Concentrations of Tenofovir and Emtricitabine in Breast Milk of HIV-1-Infected Women in Abidjan, Côte d'Ivoire, in the ANRS 12109 TEmAA Study, Step 2

• DOI: 10.1128/aac.00514-10
• Publication Date: 2010-12-21T06:06:50Z
• Authors: Sihem Benaboud; Alain Pruvost; Patrick A. Coffie; Didier K. Ekouévi; Saïk Urien; Elise Arrivé; Stéphane Blanche; Frédéric Théodoro; Divine Avit; François Dabis; Jean-Marc Tréluyer; Déborah Hirt
• Keywords: Milk, Human; Anti-HIV Agents; Adenine; Infant, Newborn; Organophosphonates; Deoxycytidine; 3. Good health; 03 medical and health sciences; Cote d'Ivoire; 0302 clinical medicine; Emtricitabine; Humans; Female; Tenofovir

ABSTRACT The aim was to evaluate emtricitabine (FTC) and tenofovir (TFV) neonatal ingestion through breast milk. Median TFV and FTC breast milk doses represented 0.03% and 2%, respectively, of the proposed oral infant doses. Neonatal simulated plasma concentrations were extremely low for TFV but between the half-maximal inhibitory concentration and the adult minimal expected concentration for FTC. The rare children who will acquire HIV despite TDF-FTC therapy will need to be monitored for viral resistance acquisition.